Rising visceral leishmaniasis in Holy Himalayas (Uttarakhand, India) – A cross-sectional hospital-based study

Sweety Kumari1, Piyush Dhawan1, Prasan Kumar Panda1, Mukesh Bairwa1, Venkatesh S. Pai1

1Department of General Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

ABSTRACT

Background: Apart from the rarity of the visceral leishmaniasis (VL) cases in high altitude (>2000 ft), the combination triad of VL, hemophagocytic lymphohistiocytosis (HLH) syndrome, and Himalayas is rarely being reported. Here, we studied the triad in the Himalayan region, attending a single tertiary care hospital over a period of 2 years. Methods: The study was a cross-sectional analysis of case records of seven confirmed VL patients. A systematic master chart review analyzed the demographic, clinical, laboratory, treatment, and outcome details of these patients. Results: These cases were diagnosed as VL by clinical findings and confirmed by rk-39 anti-body and demonstration of LD bodies in bone marrow smears. All cases without any travel history to endemic regions presented with prolonged fever (>1 months duration), anorexia, weight loss, and having hepatosplenomegaly and bi-or pan-cytopenia. All cases were having HLH, confirmed based on the HScore system (online calculation), and liver injury having transaminitis. Kidney involvement was seen in 27% cases. All cases improved with liposomal amphotericin-B, but one had cardiac arrest after blood transfusion reaction. Conclusion: Clinician of the non-endemic zone should suspect VL in patients with fever of unknown origin and have a high suspicion in cases of HLH and liver involvement and vice versa. Kidney involvement is seen in one-third of the VL cases. Liposomal amphotericin-B is recommended in this region. The leishmaniasis prevalent in these areas should further be subject to comparison with endemic parts, and a large-scale study is needed to find the reason of the rising vector from the holy Himalayas.

Keywords: Endemicity, Hemophagocytic lymphohistiocytosis (HLH) syndrome, High altitude, Kala-azar, LD bodies, Liver injury

Introduction

Visceral leishmaniasis (VL), a systemic parasitic vector borne disease, is prevalent in low-altitude areas having river belts attributing to preferential habitat of its vector, i.e. sand fly. It does rarely occur in altitudes over 2000 ft (600 m). However, in the last quarter of the twentieth century, migration of disease has been noticed and new niches being reported from previous non-endemic regions. One of them is across the Himalayas (Southern) from Pakistan to Bhutan through India. Considering Uttarakhand Himalayas of India, sporadic cases have been reported from the natives of Himalayan region such as Kumaon (350–900 m above mean sea level) and Garhwal (1500–2500 m above mean sea level) region. This phenomenon of migrations of the disease from Indian endemic locality such as Bihar and West Bengal towards the hilly regions of Himalayas points towards the new endemicity of the disease.

Access this article online

Quick Response Code:
Website: www.jfmpc.com
DOI: 10.4103/jfmpc.jfmpc_1174_19

How to cite this article: Kumari S, Dhawan P, Panda PK, Bairwa M, Pai VS. Rising visceral leishmaniasis in Holy Himalayas (Uttarakhand, India) – A cross-sectional hospital-based study. J Family Med Prim Care 2020;9:1362-9.
The disease pattern of this region also varies slightly from rest of the world as documented in the few published case reports/series. Almost all cases present as VL rather than cutaneous leishmaniasis, and the common association of VL and hemophagocytic lympho-histiocytosis (HLH) syndrome is being found.[4] HLH-associated VL is more malignant and difficult to diagnose as features of both overlap and lead to delayed treatment. Both require aggressive and early treatment for better outcomes in terms of morbidity and mortality.

This needs a study to know the demography and clinical details of VL patients in this so-called non-endemic area. Thereby, we do a cross-sectional hospital-based study of all adult VL cases who are coming from Uttarakhand state of India and admitted in our hospital (General Medicine Department) during the last two years.

Materials and Methods

This cross-sectional study was conducted during July 2017 to June 2019 in a referral 1000-bedded tertiary health center in Rishikesh, located in the base of Uttarakhand (state full of Himalayas), India.

Case records of all patients \( n = 10 \) with VL (confirmed diagnosis), admitted to the Department of General Medicine of the hospital in the last two years, were scrutinized. Seven patients were included in the study after the inclusion criteria of Uttarakhand residential address.

The demographic, clinical, laboratory, treatment, and outcome details of all seven patients were entered in a systematic master chart excel. HLH was diagnosed based on diagnostic criteria and HScore calculated by online software http://saintantoine.aphp.fr/hscore predicted the possibility of HLH [Table 1].[5,6] Diagnosis of acute kidney injury (AKI) was made based on the KDIGO definition. Either or both hyperbilirubinemia (total bilirubin >2.5 mg/dL) and transaminase elevation (more than twice the upper limit of normal) were used to classify as acute liver injury (ALI) after excluding the prior history of liver diseases.

Results

During the last two years, we found seven cases of VL proven by rk-39 (point of care test for leishmaniasis) and later confirmed by bone marrow examination. Majority of them (except few having atypical features) presented with prolonged (>1 months) high-grade fever with chills, rigor, malaise, anorexia, and unintentional weight loss without the history of any localizing symptoms [Table 2]. None of them gave any history of IV drug abuse, exposure to STDs, or travel to endemic region of VL (within a period of 1 year). Most of them had pancytopenia and hepatosplenomegaly.

Other local causes of prolonged fever like malaria, enteric fever, scrub typhus, tuberculosis, HIV, HCV, and HBV were ruled out except case 7 that had HBsAg positive. Bone marrow examinations showed LD bodies confirming VL [Table 3]. During further evaluation, serum ferritin and triglyceride were found to be raised, so possibility of HLH syndrome was suspected and HScore calculated. All had >90% probability of HLH (secondary to VL). However, NK cell activity and sCD25 level could not be done due to unavailability. Final diagnosis of VL with secondary HLH was considered. All cases except one improved after treatment with either plain amphotericin-B (never alone) and or liposomal amphotericin-B depending upon affordability and preferences. Positive response was considered to have informed of absence of fever, decrease in spleen size, and improving hematological parameters. All were discharged on due course and doing well on follow up except one who died during hospital course.

Few atypical findings were observed. All cases had liver involvement in the form of transaminitis and three had jaundice. Two cases had anasarca and kidney injury. One had gastrointestinal manifestation. Although case 6 had been diagnosed as VL 4-5 months before by haematology department, but she deferred treatment and after 2 months she presented with intermittent bleeding lips and progressive anasarca. She developed transfusion reaction after the transfusion of packed RBC with acute lung injury and suddenly went to irreversible cardiac arrest.

Discussion

The present study focuses on cases, presenting as fever of unknown origin (F/UO) from hilly regions of Southern Indian Himalayas, and later on unexpectedly proven to be VL. These cases were native of Uttarakhand (mainly areas near the river belts, especially Ganga), neither visited to endemic zone nor having any contacts with people of that zone except case 3 and 7 having h/o contact with Bengali and Bihari laborers, suggesting the possibility of expansion of endemicity [Figure 1]. All cases were proven to have HLH (>95% chance based on Hscore) and liver involvement. Hence, expansion of disease territory and variation in disease manifestations are more concern.

Previous case reports of VL from different regions of Uttarakhand are mainly distributed along the banks of river Ganges [Table 4],[5,7-12] But there is lack of data and research regarding whether the parasite and its vector have developed as a new species in these areas or introduced de novo by migrant population. Although the latter appears more likely, as one study suggests the possibility of ecological changes causing an environmental shift in favor of vector proliferation, due to the development of Tehri dam reservoir and migration of laborers from endemic areas.[13] Also, the possibility of the upstream move of sandflies along the Ganges from endemic zone cannot be excluded as has been suspected in our study in the map. Each primary care physicians should consider this possibility now in this non-endemic region.
Clinical presentation of cases varies compared to endemic cases. For example, most of the cases till now, reported from this area, are of VL rather than cutaneous leishmaniasis similar to our study. Liver function derangement is infrequent in VL although the parasite primarily infects the reticuloendothelial system and hepatomegaly is common. In previous Indian studies, biochemical evidence of hepatitis was found in 25%, 17%, and 51% of VL patients, respectively. In our study, 43% had direct hyperbilirubinemia, 70% had hypoalbuminemia, and all had transaminitis (100%), although none had evidence of other causes of hepatitis except case 7 having positive HBsAg. This 100% liver involvement could be a part of HLH since all of our cases had the same. This supports HLH goes hand in hand with VL in this region.

VL is one of the major infective causes of HLH. The clinical picture of both is often overlapping and bone marrow may fail to reveal LD bodies. Consequently, VL might be missed and intense immunosuppression for HLH without specific antimicrobial therapy may be administered with disastrous consequences.
Kumari, et al.: Expanding Kala-azar in non-endemic region (Himalayas, India)

is seen in hilly area as per one study, but our study could not establish this relationship.

Case no 6 had epistaxis and bleeding lips, mostly due to thrombocytopenia or deficient clotting factor as suggested by Sigdel et al. Bilateral pleural effusion is also a very rare finding in immunocompetent VL cases and has been reported only in few cases from endemic cases.

Treatment for VL and associated HLH is mainly amphotericin-B either as a single dose of liposomal one or multiple doses of plain one. An efficacy of 95.7% is seen with a single-dose regimen of liposomal amphotericin B at a dose of 10 mg/kg, along with the lower toxicity and shorter duration of therapy. However, multiple doses of 18–21 mg/kg plain amphotericin-B have 90%–100% efficacy in southern Europe with many adverse effects, which necessitate close monitoring and hospitalization for 4–5 weeks, which ultimately increases the cost of therapy.
Table 3: Laboratory (initial) characteristics of seven cases diagnosed as visceral leishmaniasis

| Parameters | 1     | 2     | 3     | 4     | 5     | 6     | 7     |
|------------|-------|-------|-------|-------|-------|-------|-------|
| Hemoglobin (gm%) | 7.8   | 9.6   | 7.0   | 10.6  | 6.7   | 6.2   | 8.08  |
| Total leukocyte count (cells/mm³) | 2500  | 2290  | 2200  | 1500  | 4000  | 3500  | 42000 |
| Platelets (×10³) | 1.2 lakh | 1.2   | 2.1   | 1.2   | 1.05  | 1.2   | 4.3   |
| Total bilirubin (mg/dL) | 1.15  | 2.0   | 1.2   | 1.05  | 2.4   | 0.54  | 3.74/4.85 |
| Aspartate aminotransferase (AST) (IU) | 734   | 57    | 1.2   | 1.05  | 2.4   | 0.54  | 3.74/4.85 |
| Urea (mg/dL) | 45/1.56 | 40/1.12 | 45/1.56 | 40/1.12 | 45/1.56 | 40/1.12 | 45/1.56 |
| Serum ferritin (ng/dL) | >1650 | >1650 | >1650 | >1650 | >1650 | >1650 | >1650 |
| BM findings | Leishman Donovan (LD) bodies | Leishman Donovan (LD) bodies | Leishman Donovan (LD) bodies | Leishman Donovan (LD) bodies | Leishman Donovan (LD) bodies | Leishman Donovan (LD) bodies | Leishman Donovan (LD) bodies |
| HScore | 219/196/96.9% | 219/196/96.9% | 219/196/96.9% | 219/196/96.9% | 219/196/96.9% | 219/196/96.9% | 219/196/96.9% |

Figure 1: Terrain map showing distribution of seven visceral leishmaniasis cases (in orange colored) and previous published studies (in blue colored) in Uttarakhand Himalayas and trace of river Ganga along with endemic locations (inlet, Indian map having colored states: Uttar Pradesh, Bihar, Jharkhand, and West Bengal) of leishmaniasis. Map courtesy: Terrain map scaled down from Google Map® – modified in compliance with in-app permissions and policies.

Amphotericin-B may inhibit macrophage function, cytokine expression, antigen-induced proliferation of T and B cells in vitro, and the function of cytotoxic T cells. Therefore, it may have exerted a dual effect on both HLH and VL in our study. All our cases respond to liposomal molecule including one case that failed from plain amphotericin-B. This suggests importance of liposomal over plain amphotericin-B, especially a note for physicians in this community.

Our study had its own set of limitations. First, this study was of small sample size and short follow up. However, in a non-endemic area, this may be significant. Second, the data collected were dependent on medical records. Third, our work is based on the characteristics of the study population, which was from a tertiary care center and most likely represents a more severe disease spectrum. Therefore, the disease prevalence might have been underestimated. Lastly, the study did not account negative diagnostic test results during the study period. Since pointers to think for VL/HSH depend upon experiences of concerned doctors of this study, good documentation quality and knowledge capacity of the doctors are to be taken care in future studies to answer this question. Findings in our study are similar to few studies done before, adding validity to the data. Since this study was done in non-endemic zone for VL, the result is valid to whole Himalayas where VL may be a rising threat. This may serve as a benchmark for further epidemiological study for case detection.
### Table 4: Summary of published articles on leishmaniasis in Uttarakhand Himalayas\(^2,3,7-12\)

| Citations | Sample size | Location | Agent details | Host details | Vector details | Environmental factors studied | Nearby river | Authors Conclusion |
|-----------|-------------|----------|---------------|--------------|----------------|-------------------------------|--------------|---------------------|
| Ahmad S, et al 2016 | 33 (excludes 14 pediatric cases as below) | Garhwal region of Uttarakhand (India) | Leishmania, species not identified | CP: VL - prolonged fever, hepato-splenomegaly, pancytopenia, negative HIV status, and Hemophagocytosis. Rx: Sodium stibogluconate, both types of amphotericin-B, and miltefosine | Not documented | Altitude: 1500-4000 m above sea level. The patients had never visited any of the endemic areas. Development of Tehri dam reservoir, migration of laborers from Bihar and endemic areas, and the ecological changes have apparently caused an environmental shift in favor of vector proliferation | Ganges | The protozoan is de novo from Uttarakhand. However, molecular mapping is needed to confirm the ancestry. |
| Bhatt NK, et al 2016 | 14 | Garhwal region of Uttarakhand (India) | Leishmania, species not identified | CP: VL - prolonged fever, hepato-splenomegaly, lymphadenopathy, pancytopenia, negative HIV status, and Hemophagocytosis (HLH - 7 cases). Rx: Sodium stibogluconate | Not documented | -do- | -do- | The protozoan appears to have established a local transmission cycle, although local vector and probably an animal reservoir remain elusive. Epidemiological studies are needed to identify the vector and animal reservoir if any. |
| Chandra H, et al 2014 | Seven | Different areas of Uttarakhand (India) | Leishmania, species not identified | CP: VL - fever, hepato-splenomegaly, hemophagocytidymphohistiocytosis (HLH) syndrome. Rx: plain Amphotericin B | Not documented | Altitude?? | Ganges | In all HLH cases, leishmaniasis should be suspected. HLH diagnosis criteria may be modest while applied. VL with HLH respond well to amphotericin. |
| Mathur SB, et al 2014 | Six | Nainital (3), Champawat (1) and Pithoragarh (2) of Uttarakhand (India) | Leishmania, species not identified | CP: VL - prolonged fever, hepato-splenomegaly, pancytopenia. Rx: Liposomal (4 cases) and plain (2 cases) Amphotericin B | Not documented | Altitude: 258-1760 m from sea level. Patients never traveled to or migrated from endemic areas. | Ganges | Highlight the changing geographic distribution and the need for detailed epidemiological surveys in nonendemic regions for assessing the impact of climate change and the possibility of a zoonotic reservoir of VL in India. |
| Citations       | Sample size | Location                        | Agent details                        | Host details                                                                 | Vector details                                          | Environmental factors studied | Nearby river | Authors Conclusion                                                                 |
|-----------------|-------------|---------------------------------|--------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------|-------------------------------|--------------|-----------------------------------------------------------------------------------|
| Kumar A, et al. | 10          | Kumaon region of Uttarakhand (India) | Leishmania, species not identified   | CP: VL - fever, hepato-splenomegaly; weight loss, and pancytopenia. Rx: Intravenous sodium Stibogluconate (2, then shifted to amphi due to failure), Lip amphi-B Outcome: Survival (6 cases), lost to follow up (3), and death (1) | Not documented                                          | -do-                          | Ganges       | Highlights the changing geographic distribution and spread with implications for its control as a public health problem. Epidemiological work is required in this area to substantiate the presence or absence of any zoonotic reservoir. |
| Verma SK, et al. | Nine        | Garhwal region of Uttarakhand (India) | Leishmania, species not identified   | CP: prolonged fever, hepato-splenomegaly; pancytopenia and hypergammaglobulinaemia. Rx: Sodium stibogluconate Outcome: Survival of all cases | Preponderance of Phlebotomus argentipes (77%), which is mainly confined to cattle sheds and mixed dwellings in villages | Altitude: 1500-4000 m above sea level. The patients had never visited any of the endemic areas. | Ganges       | Sodium stibogluconate-sensitive VL is emerging in the non-endemic Garhwal region, India, and urgent and effective vector control measures may be warranted to prevent the disease from becoming a major health problem in this region. |
| Rao JS, et al.  | None        | Kumaon region (Almora&Nainital) of Uttarakhand (India) | Not applicable                      | Not applicable                                                               | Ph. argentipes (77%), Ph. papatasii (6.9%), Ph. major (2.9%), and sergentomyia (13.2%) | <do-                          | Ganges       | Ph. argentipes mainly confined to cattle sheds and mixed dwellings in the villages, mainly zoophilic, and highly susceptible to DDT (mortality, 98-100%). |
| Singh S, et al. | Five        | Kumaon region (Almora and Nainital) of Uttarakhand (India) | Leishmania, species not identified   | CP: VL - fever, hepato-splenomegaly; weight loss, and pancytopenia. Rx: Intravenous sodium Stibogluconate Outcome: Survival of all cases except one death | Not documented                                          | Altitude: 350-960 meters from sea level.                         | Ganges       | This advice for further research into the epidemiology of vector and warns about the emerging pattern in non-endemic areas. |
versa. Similarly, liver involvement is to be considered in VL/HLH cases and vice versa. Kidney involvement is seen in one-third of the VL cases. Liposomal amphotericin-B is recommended over plain one in VL cases in this region. Furthermore, VL cases should further be subject to comparison with those found in other endemic parts of India so as answer and fill the gap of knowledge about increasing prevalence and variances of VL in this region.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Authors’ contribution
Sweety Kumari and Piyush Dhawan searched the literature, collected the data, drafted, reviewed, and approved the study. Prasan K. Panda, Mukesh Bairwa, and Venkatesh S. Pai searched the literature, drafted statistically, critically reviewed, and approved the study.

References
1. Park K. Leishmaniasis. In: Park K, editor. Park’s Textbook of Preventive and Social Medicine. VI ed. Jabalpur, India: Banarsidas Bhanot; 2007. p. 256-8.
2. Singh S, Biswas A, Wig N, Aggarwal P, Sood R, Walli JP. A new focus of visceral leishmaniasis in sub-Himalayan (Kumaon) region of northern India. J Commun Dis 1999;31:73-7.
3. Bhat NK, Ahuja V, Dhar M, Ahmad S, Pandita N, Gupta V, et al. Changing epidemiology: A new focus of Kala azar at high-altitude Garhwal region of North India. J Trop Pediatr 2017;63:104-8.
4. Pawar S, Ragesh R, Nischal N, Sharma S, Panda PK, Sharma SK. Unique triad of ‘Pregnancy, Kala azar and hemophagocytic lymphohistiocytic syndrome from a non-endemic region’. J Assoc Physicians India 2015;63:65-8.
5. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: Advances in patho-physiology, diagnosis, and treatment. J Pediatr 2013;163:1253-9.
6. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66:2613-20.
7. Ahmad S, Chandra H, Bhat NK, Dhar M, Shirazi N, Verma SK. North Indian state of Uttarakhand: A new hot house of visceral leishmaniasis. Trop Doct 2016;46:111-3.
8. Chandra H, Chandra S, Kaushik RM, Bhat NK, Shrivastava V. Hemophagocytosis on bone marrow aspirate cytology: Single center experience in North Himalayan region of India. Ann Med Health Sci Res 2014;4:692-6.
9. Mathur SB, Arya AK. Nonmigrant Children with Visceral Leishmaniasis from the Nonendemic Area of Uttarakhand. J Trop Pediatr 2014;60:322-5.
10. Kumar A, Rawat V, Thapliyal N, Saxena SR. Kala-azar-A case series from nonendemic area, Uttarakhand. Ann Trop Med Public Health 2013;6:355-7.
11. Verma SK, Ahmad S, Shirazi N, Kusum A, Kaushik RM, Barthwal SP. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India. Trans R Soc Trop Med Hyg 2007;101:730-2.
12. Rao JS, Sharma SK, Bhattacharya D, Saxena NB. Sandfly survey in Nainital and Almora districts of Uttarakhand with particular reference to Phlebotomus argentipes, vector of kala-azar. J Commun Dis 2001;33:7-11.
13. Aggarwal P, Walli JP, Chopra P. Liver in kala-azar. Indian J Gastroenterol 1990;9:135-6.
14. Mathur P, Samantaray JC, Samanta P. High prevalence of functional liver derangement in visceral leishmaniasis at an Indian tertiary care center. Clin Gastroenterol Hepatol 2008;6:1170-2.
15. Salgado Filho N, Ferreira TM, Costa JM. Involvement of the renal function in patients with visceral leishmaniasis (kala-azar). Revista da Sociedade Brasileira de Medicina Tropical 2003;36:217-21.
16. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003;31:174-7.
17. Sigdel B, Bhandary S, Rijal S. Epistaxis in visceral leishmaniasis with hematological correlation. Int J Otolaryngol 2012;2012:809056. doi: 10.1155/2012/809056.
18. Dasgupta S, Saha M, Chakrabarti S, Chakraborty J. Visceral leishmaniasis with pleural effusion in an immunocompetent patient. Lung India: Official organ of Indian Chest Society 2014;31:56.
19. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12.
20. WHO. Visceral leishmaniasis elimination: Intensifying surveillance to overcome last-mile challenges in Nepal. https://www.who.int/neglected_diseases/news/VL-Nepal-intensifying-surveillance-overcome-last-mile-challenges/en/. [Last accessed on 2019 Dec 26].